ISRCTN52778666 https://doi.org/10.1186/ISRCTN52778666

India Glaucoma Outcomes and Treatment Trial

Submission date 11/10/2005	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 30/03/2006	**Overall study status** Completed	
Last Edited 11/01/2021	**Condition category** Eye Diseases	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Nathan Congdon

Contact details
Wilmer 120
600 N. Wolfe Street
Baltimore
United States of America
21287
-
ncongdon@jhmi.edu

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

India Glaucoma Outcomes and Treatment Trial

Acronym
INGOTT

Study objectives
Surgery will be more effective than medicines in controlling glaucoma in India

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved by the Internal Review Boards at the Johns Hopkins University, Baltimore, USA and the Aravind Eye Hospital in India

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Glaucoma

Interventions
Medicine (timolol, latanaprost and brimonidine) versus surgery

Intervention Type
Procedure/Surgery

Primary outcome measure
1. Intraocular pressure
2. Visual acuity
3. Quality of life

Secondary outcome measures
Cataract grade

Overall study start date

01/01/2003

Completion date
01/01/2007

Eligibility

Key inclusion criteria
Glaucoma patients over the age of 30 years in India

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
700

Total final enrolment
398

Key exclusion criteria
1. Previous surgery
2. Intraocular pressure (IOP) >35

Date of first enrolment
01/01/2003

Date of final enrolment
01/01/2007

Locations

Countries of recruitment
India

United States of America

Study participating centre
Wilmer 120
Baltimore
United States of America
21287

Sponsor information

Organisation
Pfizer Inc. (USA)

Sponsor details
Corporate Headquarters
New York
United States of America
20001

Sponsor type
Industry

ROR
https://ror.org/01xdqrp08

Funder(s)

Funder type
Industry

Funder Name
Pfizer Inc.

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2012	11/01/2021	Yes	No